Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)’s traded shares stood at 0.37 million during the last session. At the close of trading, the stock’s price was $36.15, to imply a decrease of -4.92% or -$1.87 in intraday trading. The HRMY share’s 52-week high remains $52.74, putting it -45.89% down since that peak but still an impressive 30.59% since price per share fell to its 52-week low of $25.09. The company has a valuation of $2.06B, with an average of 0.33 million shares in intraday trading volume over the past 10 days and average of 346.42K shares over the past 3 months.
Analysts have given a consensus recommendation of a Buy for Harmony Biosciences Holdings Inc. (HRMY), translating to a mean rating of 1.70. Of 4 analyst(s) looking at the stock, 0 analyst(s) give HRMY a Sell rating. 0 of those analysts rate the stock as Overweight while 0 advise Hold as 4 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at $0.28.
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) trade information
After registering a -4.92% downside in the last session, Harmony Biosciences Holdings Inc. (HRMY) has traded red over the past five days. The stock hit a weekly high of 40.41 this Friday, 10/08/21, dropping -4.92% in its intraday price action. The 5-day price performance for the stock is -5.74%, and -4.47% over 30 days. With these gigs, the year-to-date price performance is 0.00%. Short interest in Harmony Biosciences Holdings Inc. (NASDAQ:HRMY) saw shorts transact 0.64 million shares and set a 2.49 days time to cover.
Analysts on Wall Street suggest a consensus price target of $52.75, implying an increase of 31.47% to the stock’s current value. The extremes give us $43.00 and $57.00 for target low and target high price respectively. As such, HRMY has been trading -57.68% off suggested target high and -18.95% from its likely low.
Harmony Biosciences Holdings Inc. (HRMY) estimates and forecasts
Looking at statistics comparing Harmony Biosciences Holdings Inc. share performance against respective industry, we note that the company has outperformed competitors. Harmony Biosciences Holdings Inc. (HRMY) shares are 25.87% up over the last 6 months, with its year-to-date growth rate higher than industry average at 395.24% against 7.00%. Revenue is forecast to grow 300.00% this quarter before jumping 60.00% for the next one. The rating firms project that company’s revenue will grow 91.90% compared to the previous financial year.
Revenue forecast for the current quarter as set by 3 analysts is $80.9 million. Meanwhile, for the quarter ending Dec 2021, a total of 3 analyst(s) estimate revenue growth to $92.16 million.Earnings reports from the last fiscal year show that sales brought in $40.07 million and $56.29 million respectively in the corresponding quarters. In this case, analysts estimate current quarter sales to rise 101.90% before jumping 63.70% in the following quarter.
Harmony Biosciences Holdings Inc. has its next earnings report out on May 11. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Harmony Biosciences Holdings Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Harmony Biosciences Holdings Inc. (NASDAQ:HRMY)’s Major holders
Harmony Biosciences Holdings Inc. insiders hold 18.85% of total outstanding shares, with institutional holders owning 74.79% of the shares at 92.15% float percentage. In total, 74.79% institutions holds shares in the company, led by FMR, LLC. As of Mar 30, 2021, the company held over 7.25 million shares (or 12.74% of shares), all amounting to roughly $239.55 million.
The next major institution holding the largest number of shares is Vivo Capital, LLC with 4.53 million shares, or about 7.97% of shares outstanding. As of the market price on Mar 30, 2021, these shares were worth $149.81 million.
We also have Fidelity Growth Company Fund and Fidelity Select Portfolios – Health Care as the top two Mutual Funds with the largest holdings of the Harmony Biosciences Holdings Inc. (HRMY) shares. Going by data provided on Apr 29, 2021, Fidelity Growth Company Fund holds roughly 1.84 million shares. This is just over 3.23% of the total shares, with a market valuation of $53.92 million. Data from the same date shows that the other fund manager holds a little less at 1.23 million, or 2.17% of the shares, all valued at about 36.16 million.